Refractory Autoimmune Diseases Clinical Trials in Shanghai, Shanghai Municipality
2 recruitingShanghai, Shanghai Municipality, China
Showing 1–2 of 2 trials
Recruiting
Early Phase 1
A Clinical Study to Evaluate the Safety and Efficacy of GT801 Injection in the Treatment of Moderate to Severe Refractory Autoimmune Diseases
Moderate to Severe Refractory Autoimmune Diseases
Vivacta Biotechnology (Shanghai) Co., Ltd.22 enrolled1 locationNCT07614191
Recruiting
Phase 1
A Study of LUCAR-G79 in Subjects With Relapsed/Refractory Autoimmune Diseases
Relapsed/Refractory Autoimmune Diseases
Nanjing Legend Biotech Co.42 enrolled6 locationsNCT07049081